Laia Montoliu-Gaya
Overview
Explore the profile of Laia Montoliu-Gaya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
942
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashton N, Keshavan A, Brum W, Andreasson U, Arslan B, Droescher M, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e14508.
PMID: 39907496
Introduction: The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case-control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer's disease (AD) versus non-AD...
2.
Huber H, Cantoni V, Altomare D, Grotschel L, Montoliu-Gaya L, Meda F, et al.
Alzheimers Dement
. 2024 Nov;
21(1):e14259.
PMID: 39614734
Introduction: Heterozygous mutations in the progranulin gene (GRN) leading to decreased progranulin levels are one of the most frequent causes of inherited frontotemporal dementia (FTD). We evaluated progranulin levels in...
3.
Kac P, Alcolea D, Montoliu-Gaya L, Fernandez S, Rodriguez J, Maure L, et al.
medRxiv
. 2024 Nov;
PMID: 39574868
Background: All individuals with Down Syndrome (DS) will develop full-blown Alzheimeŕs disease (AD) pathology by age 40, decades before the occurrence of sporadic late-onset AD. Understanding this strong biological relation...
4.
Petersen M, Flores-Aguilar L, Head E, Montoliu-Gaya L, Strydom A, Pape S, et al.
Alzheimers Dement
. 2024 Nov;
21(1):e14364.
PMID: 39535517
Blood-based biomarkers continue to be explored for disease detection, monitoring of progression, and therapeutic outcomes as the diagnostic determination of Alzheimer's Disease in Down Syndrome (DS-AD) remains challenging in clinical...
5.
Ashton N, Keshavan A, Brum W, Andreasson U, Arslan B, Droescher M, et al.
medRxiv
. 2024 Sep;
PMID: 39228740
Background: Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer's disease (AD) pathology. Multiple p-tau biomarkers on several analytical platforms are poised for clinical use. The Alzheimer's Association Global...
6.
Lantero-Rodriguez J, Camporesi E, Montoliu-Gaya L, Gobom J, Piotrowska D, Olsson M, et al.
Mol Neurodegener
. 2024 Jul;
19(1):54.
PMID: 39026372
Abnormal accumulation of misfolded and hyperphosphorylated tau protein in brain is the defining feature of several neurodegenerative diseases called tauopathies, including Alzheimer's disease (AD). In AD, this pathological change is...
7.
Kolanko M, Huber H, David M, Montoliu-Gaya L, Simren J, Blennow K, et al.
Brain Commun
. 2024 Jun;
6(3):fcae151.
PMID: 38903933
An accurate diagnosis of neurodegenerative disease and traumatic brain injury is important for prognostication and treatment. Neurofilament light and glial fibrillary acidic protein (GFAP) are leading biomarkers for neurodegeneration and...
8.
Kac P, Gonzalez-Ortiz F, Emersic A, Dulewicz M, Koutarapu S, Turton M, et al.
Nat Commun
. 2024 Mar;
15(1):2615.
PMID: 38521766
Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212,...
9.
Lantero-Rodriguez J, Salvado G, Snellman A, Montoliu-Gaya L, Brum W, Benedet A, et al.
Mol Neurodegener
. 2024 Feb;
19(1):19.
PMID: 38365825
Background: Novel phosphorylated-tau (p-tau) blood biomarkers (e.g., p-tau181, p-tau217 or p-tau231), are highly specific for Alzheimer's disease (AD), and can track amyloid-β (Aβ) and tau pathology. However, because these biomarkers...
10.
Huber H, Blennow K, Zetterberg H, Boada M, Jeromin A, Weninger H, et al.
Alzheimers Dement
. 2024 Jan;
20(4):2340-2352.
PMID: 38284555
Background: We aimed to evaluate the precision of Alzheimer's disease (AD) and neurodegeneration biomarker measurements from venous dried plasma spots (DPS ) for the diagnosis and monitoring of neurodegenerative diseases...